Newsroom

Strive to Deliver Breakthroughs

  1. August 31, 2022

    Harbour BioMed Announces 2022 Interim Results: Revenue Grows by 1155% with Landmark Acceleration in Core Innovation Strength and Platforms Value

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands -  August 31, 2022   Harbour BioMed (“HBM”, or the "Company”; HK...

    View more
  2. August 09, 2022

    Harbour BioMed to Announce 2022 Interim Results on August 31, 2022

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – Aug 9, 2022   Harbour BioMed (the “Company”, HKEX: 02142) announced that it will repor...

    View more
  3. August 08, 2022

    PNAS Published Preclinical Results of Harbour BioMed’s Next-Generation Fully Human Heavy-chain Antibody Porustobart

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— Aug 8, 2022   Harbour BioMed (the “Company”, HKEX: 02142) announced that the preclinica...

    View more
  4. June 27, 2022

    Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 27, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that the U.S. Food and Dr...

    View more
  5. June 08, 2022

    Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 8, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Medica...

    View more
  6. June 01, 2022

    Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — Jun 1, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical ...

    View more
  7. May 25, 2022

    Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 25, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully ...

    View more
  8. May 10, 2022

    Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 10, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical...

    View more
  9. May 06, 2022

    Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 6, 2022   Harbour BioMed (“HBM”, HKEX:02142), a global biopharmaceutical company co...

    View more
  10. April 14, 2022

    Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - April 14, 2022   Harbour BioMed (“HBM” or the “Company”; HKEX: 021...

    View more